News & Views
Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging
Read more
Health Canada Approves Illuccix® for Prostate Cancer Imaging
Telix announces that Health Canada has approved Illuccix® [kit for the preparation of gallium (68Ga) gozetotide injection] for use in staging and re-staging intermediate and high-risk prostate cancer and localizing…
Read more
Join Telix at EANM 2022 to discover how nuclear medicine is shifting perspectives in Genitourinary Oncology
Read more
The Role of Patents in Drug Development – Telix in Australian Biotechnology Journal
News,
As printed in Australasian Biotechnology Journal September 2022 | Volume 32 | Number…
Read more
First Patient in New Zealand Dosed with Illuccix® – Telix’s Prostate Cancer Imaging Agent
Telix today announces the first commercial dose in New Zealand of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as 68Ga-PSMA-11…
Read more
First Patient in Australia Dosed with Illuccix® – Telix’s Approved Prostate Cancer Imaging Agent
Telix today announces the first commercial dose in Australia of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as 68Ga-PSMA-11…
Read more
First Patient Enrolled in ProstACT TARGET Study
Telix and GenesisCare, the largest provider of integrated cancer care in Australia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix’s…
Read more